Gan & Lee commences Phase III clinical trial of GLP-1 RA in China

Gan & Lee Pharmaceuticals has commenced the Phase III GRADUAL-3 clinical trial to assess the once-monthly administration of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (GZR18) in adults with overweight or obesity in China. The trial aims to evaluate the safety and effectiveness of the injection for weight management, focusing on sustaining weight loss and promoting long-term treatment adherence.

In GRADUAL-3, bofanglutide will be administered subcutaneously every four weeks over a 24-week period. The primary outcomes being measured are the percentage change in body weight and absolute change from baseline at week 24.

Professor Linong Ji of Peking University People's Hospital is serving as the principal investigator for the study. This trial follows Gan & Lees prior Phase III studies, GRADUAL-1 and GRADUAL-2, which examined bofanglutide for weight management in adults with overweight or obesity.

GRADUAL-3 is designed to determine whether a monthly dosing schedule can enhance long-term adherence and help participants maintain weight loss, thanks to reduced injection frequency. The GRADUAL programme, encompassing these three Phase III trials, targets over 1,000 participants across China to evaluate the injections effectiveness for weight reduction.

GRADUAL-1 was a 52-week study involving approximately 630 adults who did not achieve sufficient weight loss through diet and exercise alone. GRADUAL-2, also lasting 52 weeks, included around 471 adults and compared bofanglutide with Wegovy in participants with or without type 2 diabetes.

The GRADUAL-3 trial focuses on sustaining weight loss through once-monthly dosing. Bofanglutides safety and tolerability profile remains consistent with other GLP-1 receptor agonists, and its global clinical development is currently in Phase III.

Analysis: Phase III GRADUAL-3 Trial and Its Potential Impact on Weight Management

The ongoing Phase III GRADUAL-3 clinical trial, initiated by Gan & Lee Pharmaceuticals, marks an important step forward in the development of the glucagon-like peptide-1 receptor agonist (GLP-1 RA), bofanglutide (GZR18), as a treatment for overweight and obesity. This trial is distinct in its design, aiming to assess the feasibility and effectiveness of a once-monthly dosing regimen for managing weight, an aspect that could significantly impact long-term adherence and patient outcomes.

Previously, the GRADUAL-1 and GRADUAL-2 trials examined the efficacy of bofanglutide in different settings, both of which involved multiple-dose schedules. The latest trial shifts the focus towards reducing the frequency of injections, a key factor in ensuring that patients remain committed to the treatment plan over time. This could be especially beneficial for individuals who struggle with regular injections, thus potentially improving their chances of sustaining weight loss over the long term.

With over 1,000 participants enrolled across China, the GRADUAL programme is building a robust data set that will provide invaluable insights into the safety and efficacy of this novel treatment. As of now, bofanglutide's safety profile appears to be consistent with other GLP-1 receptor agonists, which is a promising indicator for its potential approval and use in clinical practice worldwide. However, the final verdict will depend on whether the once-monthly regimen offers tangible benefits in terms of sustained weight loss and patient adherence compared to existing treatments on the market.

The results of the GRADUAL-3 trial will be crucial for determining if monthly dosing can truly address the challenges of long-term weight management, and whether this form of treatment will find its place in the broader strategy of combating obesity and related conditions. The outcomes could influence both clinical practices and patient choices, potentially offering a new avenue for individuals struggling to manage their weight effectively.

Sources:

• Gan & Lee begins Phase III GLP-1 RA clinical trial in China